Enanta Financial Statements From 2010 to 2024

ENTA Stock  USD 8.83  0.27  3.15%   
Enanta Pharmaceuticals financial statements provide useful quarterly and yearly information to potential Enanta Pharmaceuticals investors about the company's current and past financial position, as well as its overall management performance and changes in financial position over time. Historical trend examination of various income statement and balance sheet accounts found on Enanta Pharmaceuticals financial statements helps investors assess Enanta Pharmaceuticals' valuation, profitability, and current liquidity needs. Key fundamental drivers impacting Enanta Pharmaceuticals' valuation are summarized below:
Gross Profit
86.2 M
Profit Margin
(1.60)
Market Capitalization
187.1 M
Enterprise Value Revenue
0.8326
Revenue
72 M
We have found one hundred twenty available fundamental signals for Enanta Pharmaceuticals, which can be analyzed and compared to other ratios and to its rivals. All investors should make sure to verify all of Enanta Pharmaceuticals prevailing market performance against the performance between 2010 and 2024 to make sure the company can sustain itself down the road. The current year's Market Cap is expected to grow to about 212 M. The current year's Enterprise Value is expected to grow to about 203.6 M

Enanta Pharmaceuticals Total Revenue

102.85 Million

Check Enanta Pharmaceuticals financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Enanta Pharmaceuticals' main balance sheet or income statement drivers, such as Depreciation And Amortization of 1.9 M, Interest Expense of 11.5 M or Selling General Administrative of 60.7 M, as well as many indicators such as Price To Sales Ratio of 5.51, Dividend Yield of 0.0 or PTB Ratio of 1.88. Enanta financial statements analysis is a perfect complement when working with Enanta Pharmaceuticals Valuation or Volatility modules.
  
Check out the analysis of Enanta Pharmaceuticals Correlation against competitors.
For information on how to trade Enanta Stock refer to our How to Trade Enanta Stock guide.

Enanta Pharmaceuticals Balance Sheet

Current ValueLast YearHistorical Average 10 Year Trend
Common Stock Shares Outstanding18.4 M21.2 M17.8 M
Slightly volatile
Total Assets333.8 M376.7 M305.4 M
Slightly volatile
Other Current Liabilities50.4 M48 M16.9 M
Slightly volatile
Total Current Liabilities60.4 M57.5 M24.2 M
Slightly volatile
Other Liabilities388.2 K408.6 K1.5 M
Slightly volatile
Property Plant And Equipment Net77 M73.3 M19.1 M
Slightly volatile
Accounts Payable4.7 MM4.3 M
Slightly volatile
Cash46.1 M37.2 M42.2 M
Slightly volatile
Non Current Assets Total58.9 M76.8 M53.9 M
Slightly volatile
Non Currrent Assets Other3.6 M3.5 M1.7 M
Slightly volatile
Other Assets5.6 M5.4 M5.1 M
Pretty Stable
Cash And Short Term Investments234.2 M248.2 M214.3 M
Slightly volatile
Net Receivables6.3 M6.6 M23.5 M
Slightly volatile
Common Stock Total Equity183.8 K239.2 K175.7 K
Slightly volatile
Short Term Investments188 M211 M172.1 M
Slightly volatile
Liabilities And Stockholders Equity333.8 M376.7 M305.4 M
Slightly volatile
Non Current Liabilities Total199.8 M190.3 M52.6 M
Slightly volatile
Other Current Assets47.3 M45 M15.5 M
Slightly volatile
Total Liabilities260.2 M247.8 M76.7 M
Slightly volatile
Property Plant And Equipment Gross70.6 M67.2 M21.3 M
Slightly volatile
Total Current Assets274.9 M299.9 M251.5 M
Slightly volatile
Common Stock190.8 K212 K174.6 K
Slightly volatile
Property Plant Equipment35.9 M34.2 M12.9 M
Slightly volatile
Current Deferred Revenue22.1 M21.1 M11.6 M
Slightly volatile
Short and Long Term Debt Total58.2 M55.5 M12.2 M
Slightly volatile
Net Tangible Assets365.3 M369.5 M299.4 M
Slightly volatile
Capital Surpluse317.9 M457.7 M295.9 M
Slightly volatile
Short and Long Term Debt790.1 K1.4 M866.1 K
Slightly volatile
Non Current Liabilities Other193.3 M184.1 M37.4 M
Slightly volatile
Deferred Long Term Asset Charges8.5 M9.6 M7.5 M
Slightly volatile
Short Term Debt1.4 M1.5 M3.3 M
Slightly volatile
Long Term Debt Total1.4 M2.1 M1.3 M
Slightly volatile
Capital Lease Obligations32 M30.5 M8.8 M
Slightly volatile
Net Invested Capital291.5 M195.1 M323.2 M
Very volatile
Net Working Capital361.1 M414 M291.6 M
Slightly volatile
Capital Stock222.4 K242.7 K202.4 K
Slightly volatile

Enanta Pharmaceuticals Income Statement

Current ValueLast YearHistorical Average 10 Year Trend
Depreciation And Amortization1.9 M2.7 M1.9 M
Slightly volatile
Selling General Administrative60.7 M57.9 M27 M
Slightly volatile
Total Revenue102.8 M67.6 M97.6 M
Slightly volatile
Gross Profit102.6 M67.6 M97.4 M
Slightly volatile
Other Operating Expenses113.7 M189.3 M109.8 M
Slightly volatile
Research Development88 M131.5 M85.1 M
Slightly volatile
Total Operating Expenses113.7 M189.3 M109.8 M
Slightly volatile
Cost Of Revenue2.6 M2.7 M26.1 M
Slightly volatile
Preferred Stock And Other AdjustmentsM2.3 M2.5 M
Slightly volatile
Interest Income13.7 M13.1 M4.8 M
Slightly volatile
Net Interest Income4.7 M7.1 M3.6 M
Slightly volatile
Reconciled Depreciation3.2 M2.7 M2.6 M
Slightly volatile

Enanta Pharmaceuticals Cash Flow Statement

Current ValueLast YearHistorical Average 10 Year Trend
Stock Based Compensation14 M26.8 M13.6 M
Slightly volatile
Begin Period Cash Flow93.8 M89.4 M44.2 M
Slightly volatile
Depreciation1.9 M1.2 M1.8 M
Slightly volatile
Capital Expenditures18.8 M17.9 M4.7 M
Slightly volatile
End Period Cash Flow44.1 M41.2 M42.6 M
Slightly volatile

Financial Ratios

Current ValueLast YearHistorical Average 10 Year Trend
Price To Sales Ratio5.513.24077.2266
Very volatile
Days Sales Outstanding65.2535.865980.4739
Slightly volatile
Stock Based Compensation To Revenue0.420.39620.1608
Slightly volatile
Capex To Depreciation15.7314.98163.5727
Slightly volatile
EV To Sales5.093.51036.2752
Pretty Stable
Payables Turnover0.40.450.4861
Slightly volatile
Sales General And Administrative To Revenue0.90.85530.3351
Slightly volatile
Average Inventory0.40.450.49
Slightly volatile
Research And Ddevelopement To Revenue2.041.94390.9926
Slightly volatile
Capex To Revenue0.280.26540.059
Slightly volatile
Cash Per Share16.4111.730715.0191
Pretty Stable
Days Payables Outstanding589663722
Slightly volatile
Current Ratio4.955.211615.1861
Slightly volatile
Receivables Turnover9.6710.176817.9786
Slightly volatile
Graham Number26.0427.411449.5369
Slightly volatile
Debt To Equity0.410.390.0917
Slightly volatile
Capex Per Share0.890.84830.2433
Slightly volatile
Revenue Per Share3.043.19687.1987
Slightly volatile
Interest Debt Per Share2.212.10460.58
Pretty Stable
Debt To Assets0.140.130.0368
Slightly volatile
Days Of Payables Outstanding589663722
Slightly volatile
Ebt Per Ebit1.120.96791.034
Pretty Stable
Long Term Debt To Capitalization0.280.270.0979
Slightly volatile
Total Debt To Capitalization0.280.270.0663
Slightly volatile
Debt Equity Ratio0.410.390.0917
Slightly volatile
Quick Ratio4.955.211615.2548
Slightly volatile
Net Income Per E B T1.030.98521.0617
Slightly volatile
Cash Ratio0.610.64712.4964
Slightly volatile
Days Of Sales Outstanding65.2535.865980.4739
Slightly volatile
Free Cash Flow Operating Cash Flow Ratio0.781.22790.9616
Pretty Stable
Fixed Asset Turnover0.880.922121.3522
Slightly volatile
Debt Ratio0.140.130.0368
Slightly volatile
Price Sales Ratio5.513.24077.2266
Very volatile
Asset Turnover0.170.17960.4273
Slightly volatile
Gross Profit Margin0.780.870.9468
Slightly volatile
Operating Cycle166187204
Slightly volatile

Enanta Pharmaceuticals Valuation Data

Current ValueLast YearHistorical Average 10 Year Trend
Market Cap212 M201.9 M208 M
Slightly volatile
Enterprise Value203.6 M193.9 M186 M
Slightly volatile

Enanta Fundamental Market Drivers

Cash And Short Term Investments248.2 M

Enanta Upcoming Events

6th of February 2024
Upcoming Quarterly Report
View
13th of May 2024
Next Financial Report
View
31st of December 2023
Next Fiscal Quarter End
View
18th of November 2024
Next Fiscal Year End
View
30th of September 2023
Last Quarter Report
View
30th of September 2023
Last Financial Announcement
View

About Enanta Pharmaceuticals Financial Statements

Enanta Pharmaceuticals stakeholders use historical fundamental indicators, such as Enanta Pharmaceuticals' revenue or net income, to determine how well the company is positioned to perform in the future. Although Enanta Pharmaceuticals investors may analyze each financial statement separately, they are all interrelated. For example, changes in Enanta Pharmaceuticals' assets and liabilities are reflected in the revenues and expenses on Enanta Pharmaceuticals' income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in Enanta Pharmaceuticals. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Current Deferred Revenue21.1 M22.1 M
Total Revenue67.6 M102.8 M
Cost Of Revenue2.7 M2.6 M
Stock Based Compensation To Revenue 0.40  0.42 
Sales General And Administrative To Revenue 0.86  0.90 
Research And Ddevelopement To Revenue 1.94  2.04 
Capex To Revenue 0.27  0.28 
Revenue Per Share 3.20  3.04 
Ebit Per Revenue(1.80)(1.71)

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
When determining whether Enanta Pharmaceuticals offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Enanta Pharmaceuticals' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Enanta Pharmaceuticals Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Enanta Pharmaceuticals Stock:
Check out the analysis of Enanta Pharmaceuticals Correlation against competitors.
For information on how to trade Enanta Stock refer to our How to Trade Enanta Stock guide.
You can also try the Bollinger Bands module to use Bollinger Bands indicator to analyze target price for a given investing horizon.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Enanta Pharmaceuticals. If investors know Enanta will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Enanta Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth
(0.66)
Earnings Share
(5.48)
Revenue Per Share
3.407
Quarterly Revenue Growth
(0.05)
Return On Assets
(0.17)
The market value of Enanta Pharmaceuticals is measured differently than its book value, which is the value of Enanta that is recorded on the company's balance sheet. Investors also form their own opinion of Enanta Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Enanta Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Enanta Pharmaceuticals' market value can be influenced by many factors that don't directly affect Enanta Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Enanta Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Enanta Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Enanta Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.